Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Dig Liver Dis ; 52(7): 695-699, 2020 07.
Article in English | MEDLINE | ID: mdl-32425732

ABSTRACT

We conducted a survey to investigate to what extent the fear of COVID-19 has influenced the patients decision to undergo or to cancel endoscopic procedures. We collected data from 847 patients from 13 centres. The main indication for endoscopy was anemia, followed by pain and unexplained weight loss. The percentage of not presenters progressively increased throughout the three weeks of study, from 15.1% at the beginning to 48.2% at the end. 37 (34.2%) upper GI endoscopies and 112 (56.3 %) colonoscopies showed an organic cause explaining the symptoms presented by the patients, respectively; 5 cases of gastric cancer (4.6%) and 16 cases of colorectal cancer (CRC) (6.0%), respectively, were detected; during the second week the percentage of organic diseases found at upper endoscopy was 19 (33.3%) with 5 cancer (8.7%), and 61 (49.1% ) at colonoscopy, with 2 CRC (1.6%); finally, during the third week the corresponding figures were 19 (48.7%) for upper GI examinations, with 3 gastric cancers (7.7%), and 43 (60.5%) with 4 (6.5%) CRC cases found.We conclude that patients weighted the fear of having a clinically relevant disease with the fear of becoming infected by coronavirus, and a relevant percentage of them (29.4%) decided not to attend the endoscopy suites at the scheduled date.


Subject(s)
Colorectal Neoplasms , Coronavirus Infections , Endoscopy, Gastrointestinal , Fear , No-Show Patients , Pandemics , Pneumonia, Viral , Stomach Neoplasms , Attitude to Health , Betacoronavirus/isolation & purification , COVID-19 , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/epidemiology , Colorectal Neoplasms/physiopathology , Colorectal Neoplasms/psychology , Coronavirus Infections/epidemiology , Coronavirus Infections/psychology , Coronavirus Infections/transmission , Disease Outbreaks , Endoscopy, Gastrointestinal/psychology , Endoscopy, Gastrointestinal/statistics & numerical data , Female , Humans , Italy/epidemiology , Male , Middle Aged , No-Show Patients/psychology , No-Show Patients/statistics & numerical data , Outcome Assessment, Health Care , Pneumonia, Viral/epidemiology , Pneumonia, Viral/psychology , Pneumonia, Viral/transmission , SARS-CoV-2 , Stomach Neoplasms/diagnosis , Stomach Neoplasms/epidemiology , Stomach Neoplasms/physiopathology , Stomach Neoplasms/psychology , Surveys and Questionnaires
2.
Dis Esophagus ; 12(1): 41-6, 1999.
Article in English | MEDLINE | ID: mdl-10941860

ABSTRACT

The present study evaluates the role of oesophageal manometry in clinical practice. Over 5 years, 347 consecutive patients were evaluated in our oesophageal laboratory. The reasons for referral were: dysphagia (11.5%), gastro-oesophageal reflux disease (GORD) (46.7%), non-cardiac chest pain (28.5%), connective tissue disease (6.9%) and other symptomatology (6.3%). Patients were classified into the following five groups according to the referral diagnosis: dysphagia (40 patients), gastro-oesophageal reflux disease (GORD) (162 patients), non-cardiac chest pain (99 patients), connective tissue disease (24 patients) and other symptomatology (22 patients). Abnormalities in oesophageal motility were detected in 90% of patients with dysphagia, in 40.1% of patients with GORD, in 47.5% of subjects with non-cardiac chest pain, in 45.8% of patients with connective tissue disease and in 18.2% of subjects with other symptomatology. The high prevalence of abnormalities in the dysphagia group was statistically significant (p < 0.001), and the range of 95% confidence intervals (0.81-0.99) suggests that the value found may be a reasonably good estimate of percentage of anomalies detectable in the dysphagia patient population. In the dysphagia group, the initial diagnosis was confirmed in 40% of patients and changed in 52.5%; in only 7.5% of cases were the manometry results not relevant for determining an appropriate diagnosis. Manometry substantially contributed to patients receiving the correct treatment in 82.5% of cases (p < 0.001 among all groups). In the GORD group and in the non-cardiac chest pain group, the results of manometry were not relevant for confirming or changing a diagnosis in 59.8% and 53.5% of cases respectively; nevertheless, in both groups, on the basis of manometry results, the treatment was changed in 42.5% of patients (p < 0.01 vs. other symptomatology group). In conclusion, on the basis of the present data, we can emphasize the usefulness of oesophageal manometry assessment in patients with dysphagia or non-cardiac chest pain, with negative routine examinations, and also in patients with refractory GORD who have been considered for antireflux surgery.


Subject(s)
Chest Pain/etiology , Deglutition Disorders/diagnosis , Gastroesophageal Reflux/diagnosis , Manometry , Aged , Female , Humans , Male , Middle Aged
3.
Endoscopy ; 30(4): 360-6, 1998 May.
Article in English | MEDLINE | ID: mdl-9689509

ABSTRACT

BACKGROUND AND STUDY AIMS: The choledocho-choledochostomy (CCS) stricture is one of the most frequent complications occurring after liver transplantation. Endoscopic retrograde cholangiography (ERCP) is the most sensitive method used to define the presence and narrowness of the stricture. Endoscopic stenting of the strictured anastomosis could provide an effective alternative to the surgical intervention. PATIENTS AND METHOD: ERCP was performed in 36 of 210 patients with liver transplantation and acute cholestasis or jaundice: in 15 cases biliary anastomotic stricture was found. These patients were endoscopically treated by long-term stenting of the common bile duct (CBD) (1 year) and followed up for more than 12 months after stent removal. RESULTS: In all cases the stenting procedure resolved the biliary obstruction syndrome within 7 days. At the end of the stenting period the CCS was dilated enough to allow adequate bile flow and absence of cholestasis. Moreover, in most patients (10) the anastomosis was kept patient for more than 1 year after stent removal, whereas only two patients had stricture recurrence and needed endoscopic restenting. Four patients dropped out of the study, respectively because of liver rejection (two), acute liver failure (one) and myocardial infarction (one). One patient who developed a stone of the transplanted CBD underwent surgical intervention. CONCLUSIONS: According to our data, the endoscopic stenting of the CBD might be considered as the first choice procedure in the setting of the biliary anastomotic strictures occurring after liver transplantation. It has proved to be safe and effective, avoiding the need for more invasive surgery, which in any case should be considered for nonresponsive patients.


Subject(s)
Choledochostomy/adverse effects , Cholestasis/surgery , Endoscopes , Liver Transplantation/adverse effects , Stents , Adult , Anastomosis, Surgical/adverse effects , Cholangiopancreatography, Endoscopic Retrograde , Cholestasis/etiology , Constriction, Pathologic/surgery , Endoscopy/methods , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prospective Studies , Treatment Outcome
4.
Endoscopy ; 28(2): 234-8, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8739739

ABSTRACT

BACKGROUND AND STUDY AIMS: The effect of sclerotherapy of esophageal varices on the development of gastric varices is a controversial question. The aim of the present study was to evaluate prospectively the presence and development of gastric varices as a consequence of esophageal variceal sclerotherapy. PATIENTS AND METHODS: We prospectively studied 227 patients, all of whom had liver cirrhosis at the time of the first bleeding episode due to esophageal varices. All patients were treated with emergency endoscopic sclerotherapy, and further courses of sclerotherapy to eradicate the varices were given at seven-day intervals for three sessions, and then every fifteen days until eradication was complete. At the time of inclusion in the study, patients were divided in two groups: group A, with initial gastric varices, and group B, without any gastric varices initially. RESULTS: Group A included 138 patients (60.8%), in 99 of whom (71.7%) disappearance of the gastric varices was observed. In 63 cases (63.6%) the varices were eliminated during the sclerotherapy treatment, before the eradication of esophageal varices; in 36 cases (36.4%), the gastric varices disappeared after the eradication of the esophageal varices. Group B included 89 patients (32.9%); in 78 of them (87.6%), no appearance of gastric varices was observed, while in 11 (12.4%), gastric varices appeared. CONCLUSION: From these data, it can be concluded that sclerotherapy of esophageal varices cannot be a determinant factor either for the appearance of gastric varices or for their subsequent risk of bleeding.


Subject(s)
Endoscopy, Digestive System , Esophageal and Gastric Varices/etiology , Esophageal and Gastric Varices/therapy , Sclerotherapy/adverse effects , Adult , Aged , Esophageal and Gastric Varices/complications , Female , Follow-Up Studies , Humans , Liver Cirrhosis/complications , Male , Middle Aged , Prospective Studies , Sclerotherapy/methods
5.
Scand J Gastroenterol ; 30(9): 872-5, 1995 Sep.
Article in English | MEDLINE | ID: mdl-8578185

ABSTRACT

BACKGROUND: The non-bleeding visible vessel in a peptic ulcer is the highest risk factor for a bleeding recurrence among not actively bleeding lesions. Perendoscopic injection of sclerosing compounds is usually used as prophylaxis against rebleeding. METHODS: Forty-two patients with visible vessels in a peptic ulcer at an emergency endoscopic procedure have been studied: 21 patients underwent prophylactic perendoscopic hemostasis, and 21 patients were infused with omeprazole intravenously. RESULTS: Eight patients (19%), four in each group, had early rebleedings (within 48 h after the enrollment). There was no significant difference between the two types of treatment. At the endoscopic control after 48 h there were significantly more lesions with higher risk of rebleeding (Forrest IIa and IIb) in the group treated with perendoscopic hemostasis. CONCLUSIONS: Our data suggest that omeprazole infusion is a valid alternative to injection treatment of non-bleeding visible vessels.


Subject(s)
Anti-Ulcer Agents/administration & dosage , Hemostasis, Endoscopic , Omeprazole/administration & dosage , Peptic Ulcer Hemorrhage/therapy , Stomach Ulcer/complications , Adult , Anti-Ulcer Agents/therapeutic use , Chi-Square Distribution , Female , Gastroscopy , Humans , Infusions, Intravenous , Male , Middle Aged , Omeprazole/therapeutic use , Peptic Ulcer Hemorrhage/diagnosis , Peptic Ulcer Hemorrhage/prevention & control , Treatment Outcome
6.
Diagn Ther Endosc ; 2(2): 93-7, 1995.
Article in English | MEDLINE | ID: mdl-18493388

ABSTRACT

The choledocho-choledochostomy stricture is one of the most frequent complications occurring after liver transplantation. Today endoscopic retrograde cholangiopancreatography may be considered one of the most common methodologic approaches for the diagnosis; at the same time it provides an effective treatment of the stenosis, avoiding more invasive surgery. Biliary flow through a strictured anastomosis definitely improves after endoscopic stenting which, in most cases, resolves the biliary obstruction syndrome; moreover, the stent could allow restoration of the anatomical and functional integrity of the common bile duct. We have successfully treated eight liver transplanted patients with biliary anastomotic stenosis by endoscopic stenting of the common bile duct or by balloon dilation (one patient). The stents were replaced every 3 to 4 months and then removed after 1 year of follow-up. We observed one patient with acute cholangitis due to the clogging of the prosthetic device.

7.
Endoscopy ; 26(9): 715-8, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7536155

ABSTRACT

Acute pancreatitis is a serious complication of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (EST). In addition, serum pancreatic enzymes increase without clinical symptoms in about 40-50% of patients undergoing these endoscopic procedures. We evaluated the potential of octreotide, a long-acting somatostatin analogue, to prevent these complications in patients who underwent EST for choledocholithiasis. 151 patients were randomly allocated to two groups (A and B). Group A was given 0.1 mg of octreotide subcutaneously 120 and 30 min before EST and four hours after; group B was given a placebo. Serum amylases (normal range 20-220 IU/l) were measured before premedication and 4, 24, and 48 hours after the end of endoscopy. After EST, the increase in the mean serum amylase was greater in the control group, but the difference was statistically significant only at the 48-hour measurement. There were five cases of acute pancreatitis in each group, with a trend (but not statistically significant) toward less severe pancreatitis in the treated group. In the control group, one patient with acute pancreatitis died. In conclusion, octreotide does not seem to prevent acute post-EST pancreatitis.


Subject(s)
Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Octreotide/therapeutic use , Pancreatitis/etiology , Pancreatitis/prevention & control , Sphincterotomy, Endoscopic/adverse effects , Acute Disease , Amylases/blood , Double-Blind Method , Female , Gallstones/complications , Gallstones/surgery , Humans , Injections, Subcutaneous , Male , Middle Aged , Octreotide/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...